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Executive Summary 
The internship report is made on financial ratios analysis of GlaxoSmithKline Bangladesh, the 
report includes the process of reviewing and evaluating the company’s financial statements 
because without this the ratio analysis can not be done.  Ratio analysis mainly calculates the 
statistical relationships between data.  The ratio analysis helps an organization to understand that 
on the last fiscal year, how their performance and it was also helps them to take decisions in 
future. 
I have selected this topic by consulting with my academic supervisor. The beginning part of my 
report contains the brief introduction of the selected company and the objectives, scope, 
methodology and limitations of the study. 
In the second part, I have covered the detailed background of the company such as the history, 
global network, mission & strategy, the organizational structure, market position and an 
overview of its products and operations. 
In the third part, I have shared my internship experience at Secretarial & Legal Department of 
GlaxoSmithKline Bangladesh Ltd. Here I have presented both mine and the departmental job 
responsibilities. In this part, I have also described my observation and understanding about the 
organization. Lastly I have give some recommendation about the organization’s overall 
performance. 
 Then starts the main analysis part of my report where I have analyzed 22 ratios of consecutive 
six years. Here I have presented the result and according the result, I have interpreted the 
financial condition of GSK Bangladesh Ltd. 
In the next part, I have discussed my findings about the financial performance of 
GlaxoSmithKline Bangladesh Ltd and based on the findings I have given some recommendations 
that will help GSK to strengthen their financial base more. 
Lastly I have come with a brief conclusion and then presented appendix and necessary 
references. 
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CHAPTER 1 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
  
 
1.1Introduction 
GlaxoSmithKline (GSK) is one of the leading multinational companies in the world and the 
sector it covers is mainly the pharmaceutical industry, besides this it also concentrates on 
consumer health care products. Although the business portfolio of GlaxoSmithKline covers two 
major categories of pharmaceuticals and consumer health care but it successfully runs both 
sector. GSK has a strong Research and Development which works really hard to give best health 
facilities to the customers and keeps pace with the rapidly changing health care environment very 
well.GSK is headquartered in London, United Kingdom and the company sells its products in 
around 70 countries. GSK supplies products to 140 global markets and has over 100,000 
employees worldwide.GSK has 180 manufacturing site in 41 countries. Based on published 
annual reports of the global pharmaceuticals companies, GSK has ranked in 4th
Sensodyne
 position. GSK 
was established in 2000 through the merger between Glaxo Wellcome PLC and SmithKline 
Beecham plc. Before getting merged, the Glaxo Wellcome plc and SmithKline Beecham plc had 
gone through an acquisition and merger respectively. In the pharma sector, GSK has a huge array 
of products for major disease areas containing asthma, cancer, virus control, infections, mental 
health, diabetes and digestive conditions. In the consumer healthcare sector, it has also strong 
product offerings. In this sector, GSK produces and markets oral healthcare and nutritional 
products, drinks and over-the-counter medicines, including , Boost, Horlicks, 
Lucozade, Ribena and Gaviscon. GSK has gained leadership in four major therapeutic areas 
which include anti invectives, central nervous system (CNS) and respiratory & gastro- intestinal/ 
metabolic. Moreover, GSK is also gaining leadership in the most significant areas of vaccines 
and it has also an emerging portfolio in a very sensitive segment and that is oncology. It is 
concentrating a lot in making strong quality oncology products. 
Primary objective of the study entails the Financial Ratios Analysis of 
GlaxoSmithKline Bangladesh Limited in order to asses the performance and 
financial condition of the company. 
1.2 Objective of the Study 
Secondary objective is to fulfill my internship requirement. 
  
 
 
Defining the scope of the study is a broad aspect to be described. Definitely 
Secretarial & Finance department helped me a lot to prepare the report but still 
there were some limitations as confidentiality is strictly maintained in GSK BD 
Ltd. 
1.3 Scope of the Study 
Data Collection 
1.4 Methodology of the Study 
In order to complete the study, two types of data have been used- 
 Primary Data 
 Secondary Data 
Primary Data was collected through organizing an interview with the Finance 
Manager & Secretarial Executive. 
Secondary Data was collected mainly through the website of GlaxoSmithKline 
Bangladesh Limited. Besides these, I also studied some published reports and 
organizational documents. 
Their security concern about revealing the information was one of the biggest challenges for me. 
For ensuring confidentiality GSK authority was unwilling to share some information which were 
really needed to prepare the report. Their official website also contains a limited amount of 
information required for making a report, I mainly covered the information from annual reports 
and through the primary sources of data. Then the time duration for preparing the report was not 
enough. Lastly, due to the work load I also got limited time to prepare the report. 
1.5 Limitations of the Study 
As the internship was first practical experience for me, so it was possible for me to understand 
the whole and actual financial performance of GSK. Based on the annual reports’ data I have 
used my understanding about finance to find out the ratios and interpret the situation. So, the 
  
 
statements, recommendations and conclusions are made according to my knowledge and level of 
understanding. 
In spite of having much difficulties and limitations, I have given my best effort to accomplish the 
report successfully. 
 
 
Chapter 2 
Organizational Overview 
 
 
 
 
 
 
 
 
 
 
  
 
 
GlaxoSmithKline (GSK) is one of the world’s leading research based pharmaceutical and 
healthcare companies which is committed to improve the standard of human life through 
enabling them to do more, feel better and live longer. Activities of GSK throughout the whole 
world are presented below: 
     2.1GSK at a Glance 
 
 
Firstly, GSK is a research based pharmacetucal company which also deals 
with  consumer  health care products.
Secondly, The GSK has taken the commitment to tackle the three "priority" 
diseases identified by the World Health Organization and those three are: 
HIV/AIDS, tuberculosis and malaria .
Thirdly,GSK is currently employing around 99,000 people accross100 
countries.
Another significant information about GSK is that makes almost four billion 
packs of medicines and healthcare products every year.
Very signifant and precious launching  by GSK held in November where it 
launched ViiV Healthcare, a global specialist HIV company established by 
GlaxoSmithKline and Pfizer to deliver advances in treatment and care for 
people living with HIV. 
Consumer Health Care products of GSK have also gained huge popularity 
and have become essential household products. These are: 
Ribena, Horlicks, Lucozade, Aquafresh, Sensodyne, Panadol, Tums, and 
Zovirax.
  
 
   
 
 
 
 
 
2.2GlaxoSmithKline in Time 
. 
 
 
 
 
In One Second: Over than 30 doses of vaccines are distributed by 
GSK.
In One Minute: Over than 1,100 prescriptions are written for 
GlaxoSmithKline.
In One Hour: Spends more than US $ 450,000 to find new products 
and also donates more than US $ 148 million in cash and products to 
communities around the world.
In One Day: Over than 200 million people around the world use a GSK 
toothbrush or toothpaste.
  
 
 
 
 
2.3History of GlaxoSmithKline 
In 1873 
 
The company was oriented as Joseph Nathan & Company in New Zealand with the founding of a 
small export-import company. It started its operation as a processing unit of abundant fresh milk 
of New Zealand. The only product it was producing Glaxo Baby Food. 
 
In 1875 
 
It started to export baby food to UK Alec Nathan, son of Joseph Nathan, coined the name 
“Glaxo” from “Glactose”. 
 
 
In 1924 
 
Joseph Nathan & Company entered the pharmaceutical industry with the manufacture of Ostelin, 
the first Vitamin D preparation. The importance of the pharmaceutical market was soon realized. 
 
 
In 1935 
 
Glaxo Laboratories Limited was founded with its headquarters at Greenford, Middlesex and 
London for the production and marketing of foods and pharmaceuticals. 
 
In 1947 
 
After the 2nd
 
 world war, Glaxo developed rapidly. Glaxo Laboratories Limited absorbed its 
parent Joseph Nathan & Company, and became a public company. 
In 1963 
 
Edinburgh Pharmaceutical Industries Limited, which owned Duncan, Flock hart and Company 
Limited and MAC Far lane Smith Limited, joined Glaxo. 
 
 
  
 
In 1995 
 
Glaxo acquired 100% share, of Wellcome PLC on May 01, 1995 and formed Glaxo Welcome 
PLC. 
 
In 1998 
 
Glaxo Wellcome achieved a number of regulatory milestones for several of its key projects, such 
as ZEFFIX for the treatment of influenza. 
In 2000 
Glaxo Wellcome and SmithKline Beecham merged to form GlaxoSmithKline; a worldwide 
research based pharmaceutical company. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
  
 
The operation of the company splits into three geographical region- Europe, the USA and 
International and each of which has separate pharmaceutical and healthcare organizations. GSK 
pharmaceutical’s International regions divided into seven geographical areas. The complete 
division is shown below- 
2.4Global Operation 
 
 
 
GlaxoSmithKline Bangladesh Limited carries with it an enviable image and reputation for the 
past 6 decades. GSK Bangladesh as a subsidiary of GlaxoSmithKline plc- one of the world’s 
leading research based pharmaceutical and healthcare companies continues to be committed to 
improve the quality of human life by enabling people do more, feel better and live longer. The 
organization’s principle activities include secondary manufacturing of pharmaceutical products 
and marketing of vaccines, pharmaceutical healthcare products and healthcare drinks. 
2.5The GlaxoSmithKline Bangladesh Limited 
GSK World Wide
Europe USA International Region
Canada
China/Hong Kong
Japan
Latin America
Middle East/ North America
Sub- Saharan Africa
Asia Pacific
Bangladesh 
Sri- Lanka 
India 
Singapore 
  
 
GSK started its operation in Bangladesh in 1949 and then it was known by its corporate entity 
“Glaxo”. In Bangladesh, Glaxo then mainly used to work as an importer of Glaxo Group. Here it 
started operation in Chittagong. Gradually it became manufacturer from importer and in 1967 it 
settled its factory in Chittagong. This site is still measured as one of the Centers of brilliance in 
manufacturing and supply Chain network of GSK Ltd. 
The global corporate mergers and acquisitions have seen the evolution of the company’s identity 
in the last 6 decades. Keeping similarity with the corporate entity, the business unit of GSK in 
Bangladesh also changed its name to Glaxo Welcome Bangladesh from Glaxo because of the 
Burroughs Welcome acquisition in 1995. Again in 2002 it changed its identity to 
GlaxoSmithKline Bangladesh Ltd because of the merger with SmithKlineBeecham. 
The mega merger of the company enables it to deliver cutting edge advancements in health care 
solutions. The rentless commitment, setting of ethical standards and quality backed leading edge 
technology of the company has built a strong relationship between stakeholders and GSK 
Bangladesh. With the ever committed 680 numbers of total employees all over the country GSK 
Bangladesh, which now comprises of both Pharma and Consumer, continually strive to meet the 
GlaxoSmithKline mission. 
 One of the pioneering pharmaceutical companies in Bangladesh, GlaxoSmithKline 
started its operation in 1967. 
2.6 GSK Bangladesh Facts 
 GSK is a secondary producer, principally packaging and distributing advanced 
pharmaceuticals products produced by its parent company. Consequently, local value 
added is low. 
 In certain novelty products such as asthma and dermatology, GSK enjoys a clear 
advantage because of its parent’s excellent research efforts and product development. 
However, a significant part of the GSK’s pharma portfolio comprises of price-controlled 
“essential products”. So, GSK Bangladesh does not enjoy price advantage for such 
products. 
 Local pharma companies of Bangladesh take advantage of liberal patent regime for least 
developed countries (LDCs), sanctioned by the WTO, which shall remain in place till 
  
 
2016. They produce copies of patented products for the local market. As the subsidiary of 
a global company, GSK does not take advantage of this liberal patent regime and does 
not produce copy drugs. 
 Although GSK has trailed the overall industry in sales growth before a few years at a 
stretch due to the dominance of local manufacturers, they have managed to recover from 
that with large growth in the last couple of years. However it appears that GSK is trying 
to make up for the lack of sales growth through its consumer products business which 
brought in almost half of the total revenue in 2009. The company has reintroduced 
various health drink items like Horlicks, Boost, Maltova etc. These lead GSK Bangladesh 
to achieve almost 232% sales growth in 2009 and 500% growth in 2008. 
 The reliance on consumer products may hurt the company’s profitability in future. The 
health drink market is fairly competitive and is often supplied by non-pharma food 
companies whose core advantage is better management of retail marketing and 
distribution systems, promotional events and efficient inventory management. 
Interestingly, GSK has outsourced their distribution operation which has boosted their 
profitability. 
 Although they do not have any big expansion plan, they seemingly have improved their 
contract manufacturing revenue dramatically. However it would be interesting to see if 
that is going to be repeated in future. 
 GSK pays regular dividend and the current ratio is 74%, last year it was 85%.So, 
dividend amount is quite impressive which helps to retain shareholders and to create new 
ones. 
 
 
2.7 Mission, Strategic Intent & Spirit of GSK Bangladesh 
 
 
The mission statement of the business- “ Our global quest is to improve the quality of human 
life by enabling people to  do more, feel better and live longer” 
Mission 
 
 
Strategic Goal 
  
 
Our strategic intent states our business goal – “We want to become the indisputable leader in 
our industry.” 
Strategies: 
 Grow a diversified global company 
 Deliver more products of value 
 Simplify the operating model 
 Individual Empowerment 
 Building Trust 
 
 
“Our company spirit describes how we need to behave if we are to achieve our goal” –We 
undertake our quest with the enthusiasm of entrepreneurs, excited by the constant search for. 
Spirit  
 
 Respect for people 
Values 
 Patient Focus 
 Transparency 
 Integrity 
 
 
 
Behaviors: 
 Flexible Thinking 
 Continuous Improvement 
 Customer Driven 
 Developing People 
 Enable & Drive Change 
 Building Relationships 
 
 
Quality Statement 
“Quality is at the heart of everything we do- from the discovery of the molecule through 
product development, manufacture, supply and sale- and vital to all the services that 
support our business performance.” 
 
 
 
 
 
 
  
 
 
2.8 Operations in Bangladesh 
 
Headquarter 
GlaxoSmithKline Bangladesh Limited 
Corporate Office 
House # 2A, Road # 138. 
Gulshan-1. 
 
Registered Office & Factory 
Fouzderhat Industrial Area 
North Kattali, Chittagong. 
District Marketing Office 
 
 
 
GlaxoSmithKline Bangladesh Limited has twelve District Marketing Offices (DMO) throughout 
the country. These are divided in five zones by which GSK’s products are sold. 
 
 
 District Marketing Offices: GSK has 12 District Marketing Offices (DMO) in Bangladesh. 
The locations of DMOs are shown below- 
 
 
Zone DMO 
Dhaka Dhaka, Mymensing 
Chittagong Chittagong, Maijdee 
Comilla Comilla, Sylhet 
Bogra Bogra, Rajshahi, Rangpur 
Khulna Khulna, Jessore 
Barisal Barisal 
 
                                                                 
  
 
 
 
 
GlaxoSmithKline Bangladesh Ltd. (In Market Place) 
 
 
 
 
 
 
GSK Bangladesh Ltd’s Stock Information. 
 
 
 
 
 
 
 
 
 
                2012                  2011 
Total Value 145.39 Corer Tk 140 corer Tk 
Market Share 1.81% 1.95% 
Ranking 15th 12th 
Share Price Tk. 10 each 
Total No. of Authorized Share 20,000,000 
Authorized Share Capital Tk. 20,000,000 
Market Capitalization 6920.685 Million 
  
 
 
Distribution Channel 
Mutual Food Distributor of consumer health care product of GSK, Bangladesh. 
Zuellig Pharma Distributor of pharmaceuticals product of GSK, Bangladesh. 
 
 
 
Organizational structure of Company 
Top management:
 
 As per provisions of the Article of Association, Board of Directors holds 
periodic meetings to resolve issue of policies and strategies, recording minutes/decisions for 
implementation by the Executive Management. 
The Managing Director heads the Executive Management, the Chief Executive Officer (CEO) 
who has been delegated necessary and adequate authority by the Board of Directors. The 
Executive Management operates through further delegations of authority at every echelon of the 
line management.  
Executive Management: 
 
 
  
                                                         
Name of Directors 
Board of Directors: 
Designation Numbers of Meetings Attended 
Mr. Duncan Learmouth Chairman 1 out of 5 meetings 
Mr. M Azizul Huq Managing Director 5 out of 5 meetings 
Mr. Golam Quddus 
Chowdhury 
Non-Executive and 
Independent 
Director 
4 out of 5 meetings 
Mr. Sarwar Azam Khan Finance Director & 
Company 
Secretary 
5 out of 5 meetings 
Mr. Md. Fakeyuzzaman Non-Executive 
Director 
4 out of 5 meetings 
Mr. Rajib Barua Site Director 5 out of 5 meetings 
Mr. Pawan Sud General Manager 3 out of 5 meetings 
 
                                                                                                                                                                               
 
  
 
 
 
 
2.9 Organogram of GSK Bangladesh: 
 
 
 
 
 
                                                                                
 
 
Managing 
Director
Finance Director 
&Company  
Secretary
Finance 
Manager
Deputy  Company 
Secretary
Management  
Reporting  
Manager
IT  Manager
Internal  Audit  
Manager
Commercial  
Director
National Sales 
Manager
Marketing  
Manager
Mrketing Service 
Manager
Product  Manager 
of Vaccine
Director HR 
HR Development   
Manager
HR Manager
HR Services  
Manager
Manager 
Administration
Communication 
Manager
Medical Affairs 
Manager Site  Director
Risk and 
Compliance  
Manager
Training Manager
  
 
 
 2.10 Functional Department of GlaxoSmithKline Bangladesh Ltd 
GlaxoSmithKline, Bangladesh, Limited comprises of five major departments. They are given 
below- 
 Human Resources 
 Marketing 
 Finance 
 Medical and regulatory affairs 
 Information Technology 
Each department of GSK operates in different aspects but they are inter-related as well as 
complementary to each other. Above mentioned functional departments are worked under the 
Managing Director. The company’s delegation of authority is decentralized. The main functions 
of these departments are shown below- 
 
HR department is one of the most active departments in GSK. Previously this department was 
known as “Personnel Management” department. The company places great emphasis and 
commitment in developing the human resources as the management body believes that only the 
best people with professional competencies can contribute successfully to achieve the 
organization’s goals. GSK has two HR Division, one is at corporate head office and other one is 
Chittagong factory office. There are four functional sub-departments. They are- HR 
Development, HR Services, HR Administration and Industrial Relations. First three sub 
departments are looked after by corporate head office HR division and last one is looked after by 
Chittagong HR division. There are various functions of HR department of GSK. The main 
activities of this department are given below- 
Human Resources 
1. Recruiting and training the best pool of employees according to company’s requirement 
2. Administering  smooth  workflow in the organization 
3. Managing demands of the labors in the factory 
4. Allocating annual holidays 
5. Organizing motivational programs for employees 
6. Looking after the wage structures and waivers 
  
 
At corporate head office six-member HR division takes care of GSK, Bangladesh, LTD. The 
member and their chain of authority are shown in the organogram below- 
 
 
 
 
The pharmaceutical industry of Bangladesh has limited field for marketing. Yet in an age of high 
competition like todays, firms are heavily spending and effectively practicing marketing. The 
summary of marketing functions is given below- 
Marketing 
1. Designing and implementing sales strategies 
2. Controlling and updating distribution network 
3. Designing and carrying out promotional programs 
4. Providing marketing information services 
5. Carrying out different awareness programs 
6. Controlling international trades 
7. Keeping records of data regarding marketing activities 
8. Building up public communication network 
9. Looking after all the brands and patents 
10. Conducting marketing surveys as needed 
 
 
 
GSK gives proper importance to their finance department The financial statements of GSK have 
been prepared in accordance with Bangladesh Accounting Standards and the relevant 
requirements of the schedule to the Securities and Exchange Rules, 1987 and of the companies 
Act 1994 following the historical cost conversion. The primary tasks of finance department are 
given below- 
Finance 
1. Controlling the accounts 
2. Completing  annual budgets 
  
 
3. Allocating all kinds of payments to the staffs and managers 
4. Looking after all the revenue and expenses 
5. Conducting internal audit 
6. Keeping records through IT 
7. Facilitating local production costs 
 
 
 
Medical and Regulatory Department of GSK, Bangladesh is compiled with required number of 
doctors and qualified people. This department is primarily responsible to perform tasks like 
liaison with government for legal issue purpose, communicate with doctors, handling 
advertisements, etc. 
Medical and regulatory affairs 
 
 
The technical department of GSK is extraordinarily strong. The organization always strives for 
reaching the global standard of applications of information technology. This company is one of 
the very few companies in Bangladesh that use world class sophisticated software. 
Information Technology 
 
 
 
 
2.11 Product line of GSK, Bangladesh, Limited 
GlaxoSmithKline operates principally in two industry segments: 
1. Pharmaceuticals: prescriptions, medicine and vaccines. 
2. Consumer HealthCare: Over the counter medicines, Oral care and nutritional healthcare 
products. 
 
  
 
Product overview: 
1. Pharmaceuticals: 
GSK’s board pharmaceuticals product line includes antibiotic, antidepressant, 
gastrointestinal, dermatological, respiration, cancer and cardiovascular medications. GSK 
has a variety of vaccine products, including hepatitis A and B, diphtheria, tetanus, 
whooping cough and influenza. 
 
2. Consumer Healthcare: 
GSK Consumer Health brings oral health care, over the counter medicines and nutritional 
health care products to millions of people. 
 
GlaxoSmithKline Products  Glossary 
 
 
 
Local production 
60 products including 
Berin 
Cytamen 
Kefdrin 
Pentamox 
 
Imported product 
17 products including 
Alkeran 
Seretide 
Zinnat 
 
Vaccines 
17 products including 
Engerix-B 
Fluarix 
Synflorix 
 
 
 
Consumer Healthcare 
9 products including 
Horlicks 
Chocolate Horlicks 
Junior horlicks 
Mother Horlicks 
Horlicks Lite 
Boost 
Maltova 
Glaxose 
 
                                                                                                                                                                                
  
 
 
 
 
2.12 GSK’S Market Share & Position Comparison 
According to performance in 2012: 
 
Companies  Market Share Ranking 
SQUARE 18.78 % 1 
INCEPTA PHARMA 9.21   % 2 
BEXIMCO 8.75   % 3 
OPSONIN PHARMA 5.07    % 4 
RENATA 4.87    % 5 
ESKAYEF 4.80    % 6 
ACME 4.26    % 7 
A.C.I. 4.20    % 8 
ARISTOPHARMA 4.04     % 9 
DRUG INTERNATIONAL 3.63     % 10 
SANOFI AVENTIS 2.53     % 11 
HEALTHCARE PHARMA 1.88     % 12 
ORION PHARMA LTD 1.85     % 13 
NOVO NORDISK 1.84     % 14 
GlaxoSmithKline 1.81     % 15 
 
 
 
 
 
2.13 GSK BD’s SWOT Analysis 
SWOT is the short form for Strengths, Weaknesses, Opportunities and Threats. It is an analytical 
Construction to help summarize in a quick and concise way the risk and opportunities for any 
Corporation across the value chain.  
A good SWOT should consider both internal and external factors that influence the 
organizational operations. 
 Factors pertaining to the internal environment of the company.  These are usually 
expressed as Strengths (S) or Weaknesses (W) 
 Factors that pertaining to the external environment of the company. These are 
expressed as Opportunities (O) or Threats (T). 
 
  
 
 
 
 
 
 
Strength Weakness 
 GSK is considered as world's one of the 
leading pharmaceutical companies because of 
its performance.  
 Efficient, capable and honest workforce 
 GSK has intense demand of their product 
nationally and internationally which helps 
them to inflate their business 
 Considerable financial resources to grow the 
business 
 Proprietary technology and importance 
patents 
 Ability to take advantage of economies of 
scale 
 Better product quality relative to rivals 
 Goodwill of the company 
 Follows GMR-Good Manufacturing Practice 
 Underutilized plant capacity 
 Higher unit cost relative to key competitors 
 Group compliance due to group policy the 
company has to import raw materials form 
UK rather from neighbor countries (other than 
those which are produces locally) resulting in 
higher cost of production. 
 Lack of variety in products 
 Low pack size 
 Lack of sufficient promotional effort.  
 GSK has weaker distribution network and 
sales force are relatively low compare to 
competitors. 
Opportunities Threats 
 GSK as a multinational company has 
opportunity for expand its investment and 
has potential growth in Bangladeshi market. 
 
 Expanding the company’s product line to 
meet a broader range of customer reeds.  
 Target and acquire an untapped marketing 
for vaccines 
 Market is significantly large and growing 
 Proper utilization of vaccines may result in 
higher profit.  
 Availability of natural resources is the most 
lucrative opportunity for GSK to work with 
Bangladesh.  
 
 In Bangladesh, GSK can get labors at a very 
cheap cost. 
 High confidence brand name and quality 
 Adverse shifts in foreign exchange rates 
and trade policies of government 
 Aggressive movement of rivals 
 Slow down in market growth 
 Growing bargaining power of the end 
consumers, thus high priced medicine are 
inconvenient for them 
 Costly new regulatory requirements 
 Competitors lower prices 
 Increasing threats from local competitors.  
 
 
 
 
  
 
 
Chapter 3 
Internship Experience 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
  
 
3.1 Job Description 
It was really a great opportunity to work as an intern in a well reputed MNC like 
GlaxoSmithKline. I worked there for 3 months under the Secreterial & Legal Department 
which is a part of the Finance Department and also has a close link with the HR 
department. My main supervisor was the Deputy Company Secretary Md. Nizam Uddin. 
Besides working with Deputy Company Secretary, I have done huge tasks with Mr. 
Probal Raha who is the Secretarial Executive. Working in Secretarial department really 
gave me lots of experience about practical job life and also improved my skills a lot. For 
this reason, I will be always grateful to Md. Nizam Uddin and Mr. Probal Raha because 
they guided me always in the right track thus I can fulfill the tasks in proper manner. 
Besides of working in Secretarial & Finance Department, I have also worked in the HR 
department of the company. 
 
Tasks of Secretarial Department: 
 One of the main tasks of Secretarial department is to handle the payment issues of 
the employees. This includes all the employees in both corporate office and 
Factory site and also includes the DMOs. 
 Secretarial department keeps record of all the employees thus any payment issue 
can have the proper evidence which will help both the company and employees in 
future to negotiate properly. 
 Secretarial department keeps contact with banks for different transaction purposes 
and time to time collect the information about deposits and withdrawals about the 
accounts like Pension Fund, Dividend Payment, Provident Fund, Treasury Bills 
etc. 
 Secretarial department handles the issues like purchasing and encashment of 
Treasury Bills, providing the bonus payments and recording the loan payments 
given to the employees. 
 Secretarial department also handles the allowance issue that is given to the interns 
and that’s why they keep information of all interns thus payment can be made on 
right time. 
  
 
 Secretarial department continuously keep contacts with the Central Bank, Security 
and the Exchange commission and the Dhaka Stock exchange regarding the audit 
issues, compliance concerns and stock market operations. 
 Secretarial department along with the Finance department significantly participate 
in Annual Report making and publishing and monitoring that it is being 
completed in the exact way and also on due date. Then it is the responsibility of 
secretarial department to monitor that the Annual reports have been distributed to 
all the shareholders and this should be done at least 20days before the AGM. 
 Secretarial department also keeps record of all traveling bills that are made for 
business purposes and also the medical bills of the employees. In the employee 
list, the DMOs are also included. They have the proper right to judge that the 
expense claim is valid or not and on this issue the secretarial department’s 
decision is final. They also keep records of foreign travel bills. 
 Many medical promotional officers get motorcycles from the company in order to 
carry the products properly. It is the duty of the secretarial department to keep 
records of the motorcycle loans and if any motorcycle is lost or theft then they 
firstly collect the evidence and then decide what to do. 
  Secretarial department keeps the final settlement copies which are basically the 
details of the employees who have left the company. There the payment details of 
those employees are also kept. If any amount is due to the ex-employee it is also 
recorded and if the company has any receivable from the employee then that is 
also recorded. Secretarial Department also keeps the pensioner lists and clears the 
payments to the pensioner or the nominees of the pensioner. 
 Secretarial department also monitors that the employee database software which 
is the Vista 3P and the financial record keeping soft wares are working properly 
or not, if there is any problem then they inform the IT department and ensures that 
the problem is solved within the shortest possible time. 
 
So, in short the Secretarial department has huge responsibilities and it has to be 
updated with the HR, Communication and the IT department. At the same time, it 
needs to handle the financial and legal issues. Not only it monitors all types of 
  
 
employee payments but also needs to monitor company’s different types of bank 
accounts and legal matters. 
 
 3.2Different Aspects of Job Performance 
 
As I was a part of the Secretarial department, so I had the opportunity to assist my 
supervisor and the Secretarial Executive in different types of tasks. 
 
One of the main tasks of mine was to check and verify the expense claims of the 
DMOs. I used to follow the company rules while deciding that the expense claim 
is valid or not. 
 
Then after checking all the bills I used to input the entries in the system and then 
also used to check that all valid payments have got clearance. If there were any 
difficulties or confusions then I used to inform the Secretarial Executive. 
 
As, this department has to look after many legal issues so there were a huge files 
and my duty was to categorize and organize all the files and then keeping them in 
sequence. 
 
This department needs to contact with different institutions and individuals, in this 
regard sometimes I used to type different sorts of business letters. 
 
As the department accomplishes the payroll activities, so employees used to visit 
the department for payment purposes and in absence of supervisors, I used to 
attend them, then used to convey their messages and claims to my supervisors.  
 
Then I used to assist the secretarial executive in checking the balance amount of 
different accounts that has been inputted in the system. 
 
  
 
In my last month, one most crucial task was according to the shareholder’s 
addresses, serially putting the annual reports in envelopes and then keeping 
records that how much annual reports have been sent to the shareholders and how 
much is remaining. 
I also have worked with the Finance department and HR department; there I used 
to calculate the bills and creating newly joined employee files respectively. 
 
Besides these I had also done some other major and minor tasks. In short, I used 
to spend a very busy schedule in GSK but it was full of fun and it also helped me 
a lot to know the core official jobs. The Secretarial department taught me to be 
punctual, sincere, honest, active, efficient and most importantly it taught me how 
to communicate in the corporate world. For enhancing these abilities in me and 
for providing me such a sophisticated environment, I will be ever grateful to GSK 
and specially the Secretarial department.  
 
 
 
3.3 Critical Observation & Recommendation: 
Within the 3months’ experience in GSK, I have found that the organization is very 
organized at accomplishing the tasks, it is very much focused at doing fair business and 
the corporate environment is really safe and friendly. GSK Bangladesh truly follows the 
code of conducts which established by its parent company. All the employees here try to 
maintain integrity in their every tasks. All the departments are here properly co-ordinated 
which fosters the organizational performance a lot. Here the importance of human asset is 
truly realized and all the employees are believed as the heart of the organization and 
that’s why the employees work here with true motivation and sincerity. As I was the part 
of Secretarial department which is a section of Finance department, I have found that 
employees of these two departments are very much knowledgeable and skilled and very 
efficiently they plan and implement the financial strategies. They are also very much 
  
 
aware about utilizing the resources and not to waste the assets of the organization 
unnecessarily. 
 
 
 
I have observed and felt that GSK Bangladesh is doing excellent job, one thing that 
appeared surprising to me is in spite being so efficient at operations and having so much 
qualified products, GSK Bangladesh is in 15th
 
 position. Market leaders are the local 
firms, the reason behind this is the government concern to promote the local 
pharmaceuticals. So, GSK should take strong initiatives thus they can improve their rank 
and can lag behind the competitors. On the other hand, most of the consumer health care 
products are doing so well, especially the health drinks and the glucose powder. 
So, my recommendations are: 
GSK should concentrate more on promotional activities and making people more 
aware about their company profile and products thus a strong brand image can be 
established. 
 Like the Consumer Healthcare products, the pharmaceuticals products should be 
engaged in famous public events. 
 They should be more concerned to reduce the production cost of the pharma 
products thus they can compete with the local products more successfully. 
 
 GSK should introduce their pharma products more to the public and should 
inform the people that it is the same company which makes horlicks and boost. 
 GSK should be very careful in maintaining the copyrights of their products as 
they are in alliance with some local firms like Mutual food and Zuellig Pharma. 
 
 
 
  
 
 
 
 
 
 
Chapter 4 
Project Analysis and Findings 
 
 
 
 
 
 
 
 
 
 
 
  
 
Ratio Analysis is done to measure the financial performance of the company and to understand 
that in which track the company is going in the future. So, it is basically one technique of 
assessing the company’s financial performance.  
4.0 Ratio Analysis 
In ratio analysis, financial items of a particular year are compared. Here relationships between 
the financial items are examined. So, by doing ratio analysis we can judge the various financial 
aspects of a firm. Then when we compare one year’s ratios with another then we come to know 
that how much progress was made during the compared period. The ratio analysis is very 
important to investors, creditors and financial analysts as it helps in decision making. 
In order to evaluate GSK’s financial performance, I have also selected ratio analysis as the 
analyzing tool. 
 
4.1 Current Ratio: 
Ratios Analysis of GSK 
Current ratio is an efficient tool to measure that the organization is capable in meeting up its 
short term debts or not. Current ratio basically assesses a firm’s liquidity because, if a firm is 
enough liquid and it has enough resources then it can pay back the all debts that need to cover 
during 12 months. 
 
 
 
 
 
Formula: Current Assets ∕ Current Liabilities 
  
 
Higher current ratio definitely indicates that the firm is highly liquid and able enough to meet the 
demands of the creditors.  Satisfactory current ratio actually varies from industry to industry but 
in general, if the current ratio lies between 1.5 and 3 then it indicates that the business is healthy. 
If the current ratio is below 1then it means that the current liabilities are higher than the current 
asset, so the firm can face many difficulties while paying back short term debts. On the other 
hand if the current ratio is too high then it indicates that the firm is not efficient to utilize its short 
term financing facilities. It may also indicate that the firm has problem in working capital 
management. 
Low current ratios normally indicate that the firm is in trouble to meet current obligation but not 
necessarily always a low current ratio indicates a huge problem. Firms which have not much 
currents assets but have a strong long term plans and prospects, they definitely can sort out ways 
to tackle this problem. There are many firms who have a current ratio under 1 but they are 
surviving quite well. So, low current ratio does not always mean that the firm is at an alarming 
stage or very near to be bankrupt but of course it is better to maintain a standard current ratio in 
order to ensure fewer risks. 
From the perspective of short term creditors, a high current ratio is appreciable because it means 
that the company is eager to pay back current debts within 12 months. A high current ratio also 
indicates that the firm is much efficient to convert its goods into cash quickly.  
In short, current ratio should be compared within the same industry as the benchmark ratio varies 
from industry to industry. 
 
 
 
 
 
 
  
 
Current Ratio of GSK: 
Year 2007 2008 2009 2010 2011 2012 
Current 
Ratio 
4.64 2.96 3.11 2.59 2.05 1.79 
 
Table 1: Current Ratio 
 
 
                    2007                2008                2009                2010             2011             2012 
 
Over the six years, GSK had highest current ratio in 2007 and the amount was 4.64. This quite 
high figure indicates that GSK did not utilize its current assets to raise funds for the business 
growth. Then in 2008 it was quite low than 2007 and the amount was 2.96 which is still high but 
the decrease in the ratio indicates that on that year GSK tried to make proper use of the current 
assets. Then in 2009 it was again above 3 but in 2010 and 2011 it was in proper control. Most 
satisfactory point is that, GSK Bangladesh had no lower current ratios over these five years 
which is an indication that GSK has enough liquid assets or cash by which they can save their 
business from big troubles. In 2012, it is also in the standard level which indicates well 
performance. 
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4.2 Quick Ratio: 
This ratio assesses the capacity of an organization to recover its current liabilities by using the 
organization’s quick assets. The asset which can be turned into cash rapidly at an amount that is 
very close to its book value is known as quick asset. 
Quick ratio is also known as Acid-test ratio and liquid ratio. Any quick ratio less than 1 means 
that the firm can not pay back its current debts. 
Formula: (Current Asset-inventory) ∕ Current Liabilities 
From the formula, we can see that inventory is not included in the quick ratio, where as it is 
included in the current ratio. Always a high quick ratio is not considered as good, if it happens 
that the firm has huge account receivables but those will be collected after a long time and the 
current liabilities are lesser but needs to be paid instantly then the quick ratio will be higher but 
still the firm is in a great risk as there is liquidity crisis. On the other hand, opposite thing can be 
happen when the firm has lesser current assets which will be mature soon and more current 
liabilities which need to be paid in much later. In this case, the quick ratio will be lower but 
despite of that the firm is risk free as there is no hurry of payments. Standard quick ratio is 1:1 or 
above. Higher the quick ratio, the company is more liquid but yes the benchmark figure is 
different in different industries. 
Quick Ratio of GSK: 
Year 2007 2008 2009 2010 2011 2012 
Quick 
Ratio 
1.94 1.23 1.69 1.60 0.96 1.05 
 
Table 2: Quick Ratio 
 
  
 
 
                 2007               2008             2009             2010           2011          2012 
The graph shows that GSK Bangladesh Ltd had highest quick ratio in 2007 but was dropped in 
2008 and then again rose in 2009 and in 2010 it dropped very little . Over these four years GSK 
has maintained very efficient quick ratios these were quite high than 1 but in 2011 there was 
huge fall and the ratio was below 1 which is very disappointing. This means in 2011 GSK was 
not enough able to pay back its short term debt but if we analyze he trend then we will find that 
GSK is capable to tackle liquidity crisis and to recover from bad situations. Another important 
point is, the current ratio in 2011 was quite high than 1 which means it had enough current assets  
but yes there were lacings in quick assets. It actually means that when the current assets will 
generate cash then GSK will gain a high quick ratio. This impact we really can see in 2012, as in 
this year the ratio is 1.05 so it means GSK has recovered from the lacings in quick assets.  
4.3 Cash Ratio:  
Cash ratio is a ratio of a firm’s cash and cash equivalents to its current liabilities. This ratio is a 
great measurement of liquidity, if the ratio is high then it indicates that the firm has enough cash 
to meet up immediate payment demand. Cash ratio is very conservative at its appearance as it 
does not include any non-cash current assets, only cash on hand and cash equivalents are used to 
calculate this and for this reason the result is relatively low. A cash ratio higher than .5 is 
preferable. 
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Formula:  (Cash + Cash Equivalents) ∕ Current Liabilities 
Cash Ratio of GSK: 
Year 2007 2008 2009 2010 2011 2012 
Cash Ratio 0.1 4 0.0 1 0.73 0.95 0.63 .71 
 
Table 3: Cash Ratio 
 
 
 
                    2007           2008          2009        2010          2011          2012 
 
Here, we can see that in first two years the cash ratio was very poor which signals that GSK 
faced much liquidity crisis and had not sufficient cash in hand to pay back the short term 
liabilities. On the other hand, from 2009 to 2011 the cash ratio took huge increase and it was 
above 0.5 then. Highest cash ratio was achieved in 2010 which was .95 that means very near to 1 
which indicates that there were enough cash assets in this year. Although there was a fall in cash 
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ratio in 2011 but still that was a satisfying figure. Then more satisfying thing is, in 2012 the ratio 
increased by .08 points. 
 
4.4 Net Working Capital: Net working capital is the capital by which firms can fund its daily 
operations. It is one of the standard assessments of liquidity of an organization. This ratio finds 
out that the firms have excess current assets over the current liabilities or not. If the firm has 
higher current assets then the ratio will be positive which means the organization has the ability 
to operate daily business and to cover immediate obligations. Diminishing working capital is an 
alarm that business is going to face troubles and the worst scenario is the bankruptcy. 
Net working capital is also known as working capital and working capital ratio. It gives the 
investors another clear view of the firm which is the operational efficiency. A firm which is quite 
efficient in running business and collecting money from customers, the net working capital of 
that firm will be between 1.2 and 2 because much high working capital indicates that huge 
money is tied up in inventories and to the borrowers. So, consecutive increases in working 
capital is a signal of slow collection which is not good for business. 
Formula: 
Net Working Capital= Current Assets-Current Liabilities 
Working Capital Ratio of GSK: 
Year 2007 2008 2009 2010 2011 2012 
Working 
Capital 
Ratio 
573877 674459 905127 1120782 1086606 1132519 
                                            
                                                 Table 4: Net Working Capital 
 
  
 
 
                          2007          2008          2009         2010          2011          2012 
 
Here we can see that GSK Bangladesh Ltd has maintained positive net working capital which 
indicates their operational efficiency. From 2007 to 2010 the working capital ratio was too high 
and these were above 2 which is a sign that GSK is slow at payment collections and operating 
cycle is not enough efficient. Satisfactory thing is, in 2011 it was little high than 2 which means 
it used its current assests properly than the previous years. 
 
4.5 Inventory Turnover Ratio:  In the business, the sufficient volume of inventory is must and 
we can judge that enough inventory is being produced or not through the inventory turnover 
ratio. This ratio basically shows that over a period, how many times the inventories are sold and 
renovated in a business. Generally, a company with high inventory turnover ratio is assumed as 
strong one. When the inventory level is very high then the ratio will be low which means the 
inventories are kept idle in the warehouse so definitely it is bad for future growth. Huge amount 
of inventories also symbolize that the rate of return on the inventory investment is near to zero. 
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The turnover ratios of the unpreserved goods are normally very high as these are sold out 
quickly. Although high inventory turnover ratio is always desired but sometimes high ratio may 
also indicate ineffective buying as lower inventory purchasing will cause the ratio to be high. 
Formula: 
Inventory Turnover Ratio= Sales ∕ Inventory 
The ratio is also calculated in this manner,   
Inventory Turnover Ratio= Cost of Goods Sold  ∕ Average Inventory        
  
 
 Inventory Turnover Ratio of GSK: 
Year 2007 2008 2009 2010 2011 2012 
Inventory 
Turnover 
Ratio 
5.86 4.75 6.81 6.87 5.95 7.48 
  
                                                 Table 5: Inventory Turnover Ratio 
  
 
                           
          2007     2008     2009     2010      2011      2012 
 
 
From 2007 to 2011 GSK has maintained high inventory turnover which means that GSK had 
strong sales over last few years. Although in 2008 and 2011 there was little fall but in spite of 
that the turnover was high which means inventories are utilized properly and through those high 
sales are generated. In 2012 the ratio is higher. 
 
4.6 Inventory Conversion Period:  The inventory conversion period is the period during which 
the inventories are used to produce new goods and then preparing them for selling to the end 
users. Lower the conversion period, higher the firm’s ability to convert the raw materials into 
finished goods. 
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Formula: 
Inventory Conversion Period= (Inventory ∕ Cost of Goods Sold) × 365 days 
Inventory Conversion Period of GSK:  
Year 2007 2008 2009 2010 2011 2012 
Inventory 
Conversion 
Period 
124.56 153.64 107.17 106.19 122.74 97.54 
 
                                                 Table 6: Inventory Conversion Period 
 
   
 
                  2007         2008      2009      2010     2011      2012 
 
In case of inventory conversion period, lower figure is more acceptable. From the graph we can 
see that in 2007 it was lower but in 2008 it was quite higher which indicates less business 
efficiency. Then in 2009 it dropped a lot which is again a good sign and although in 2010 the 
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conversion period was slight high than that of 2009 but still it was much lower than 2008. So, it 
means that after 2008 GSK concentrated to increase operational efficiency. In 2011 the result 
was not satisfactory as it was 16 days higher than 2010 but if we compare with 2008 then will 
find that the inventory conversion period of 2011 is much better. In 2012 te rato is impressive as 
it took less time than previous years. 
 
4.7 Fixed Asset Turnover: It is the ratio where sales are compared with the fixed assets of the 
firm. The ratio actually clarifies that the firm is capable enough to use its fixed assets to earn 
revenues or not. In fixed asset turn over, normally investments on property, plant and equipment 
are counted and the depreciations of these are subtracted. A high fixed asset turnover is always 
appreciable as it signals towards the firm’s high productivity. Higher fixed asset turnover means 
the firm is utilizing its fixed assets and generating revenues from these. On the other hand, low 
fixed asset is the signal that the firm is not productive and the firm fails to generate sales revenue 
by utilizing the fixed assets. 
There is neither standard guideline nor a best level for fixed asset turnover, so the evaluation and 
comparison can be done by calculating fixed asset turnovers of past years of a particular 
organization. As there is no average figure, so progress of the firm can also be assessed through 
comparing fixed asset turnovers of different firms of the same industry. High fixed asset turnover 
means that less money is allocated to the fixed asset portion, where as too low fixed asset 
turnover means that additional fixed asset investment has been made which is unnecessary. So, 
the investment in fixed assets should be in the right amount, neither more nor less and most 
importantly it should be monitored that the assets are being utilizing properly thus they can 
contribute to high revenues. 
Fixed Asset Turnover = Net Sales ∕ (Plant, Property, Equipment) 
 
 
 
  
 
Fixed Asset Turnover of GSK:  
Year 2007 2008 2009 2010 2011 2012 
Fixed Asset 
Turnover 
4.72 5.49 8.23 9.87 9.85 11.16 
 
                                                      Table 7: Fixed Asset Turnover 
 
 
 
 
                 2007         2008        2009        2010       2011         2012 
GSK had an increasing fixed asset turnover from the year 2007 to 2012. Although there was a 
little bit fall in the fixed asset turnover in 2011 but the difference from 2010 is only .02 so this is 
not any significant issue. If we compare from 2007 then will find it started from 4.72 and three 
gradual increases, it reached at 9.85 in 2011 and 11.16 in 2012.so the progress is quite high. This 
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high trend actually indicates that GSK has become more efficient is asset utilization over these 
six years. 
4.8 Total Asset Turnover: Total Asset Turnover judge that how much sales revenue is gathered 
in against of each dollar of assets. Through this ratio, the effectiveness of asset management of 
the firm is measured. Higher the ratio, higher the efficacy of the firm and the vice versa. 
Total Asset Turnover = Revenue ∕ Total Assets 
From the asset turnover, we can also guess that pricing strategy as the high asset turnover signals 
towards the low profit margin which means costs have increased and need to cut down. 
Total Asset Turnover of GSK:  
Year 2007 2008 2009 2010 2011 2012 
Total Asset 
Turnover 
1.49 1.39 1.78 1.64 1.70 1.81 
                                                       Table 8: Total Asset Turnover                             
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It is a good point that the asset turnover was in increase in most of the time of the last 6 years. 
Although in 2010 there was little fall but in 2011 it recovered and in 2012 it achieved the highest 
point of 1.81 which is obviously satisfying. This increasing trend indicates that GSK is good at 
asset management but it also indicates that in 2012 the profit margin was lower than that of 2011. 
4.9 Days Sales Outstanding: It is the ratio by which we can know that within how much days 
the firm collects its money from the sales, so it means that how much times a firm takes to 
convert its accounts receivables into cash. If the ratio is lower, then it is good for the 
organization as it indicates that the organization collects its receivables at the shortest possible 
time. If an organization collects money quickly then can meet up the cash demand to operate the 
business and also can reinvest more money thus more sales can be occurred. 
Days Sales Outstanding = (Accounts Receivables × 365 days) ∕ Annual Sales 
Days Sales Outstanding of GSK:  
Year 2007 2008 2009 2010 2011 2012 
Days Sales 
Outstanding 
65.42 81.25 49.43 46.52 30.93 32.03 
 
Table 9: Days Sales Outstanding of GSK 
 
  
 
 
                   2007           2008          2009          2010        2011       2012 
The lowest DSO (Days Sales Outstanding) was achieved in 2011 which means GSK was most 
efficient at collecting money at that year and they had sufficient money to operate the business. 
In 2008, the DSO was highest which indicates towards low efficacy in managing sales but the 
positive thing is that the DSO has decreased a lot over the last six years. Although in 2012 the 
DSO was higher than 2011 but it was relatively much lower than the previous years. 
4.10 Debt Ratio: This ratio finds out that how much of the total asset is funded through debt. So, 
it actually shows the dependency on debt in order to manage assets. If the ratio is higher then it 
means that the firm has higher debt and it is more dependent to its creditors for necessary 
financing. If the ratio is higher than 1, it indicates excess debt over total assets and the vice versa. 
Although higher debt is not a problem if interest payments are made on time, if it is not then 
definitely a great risk for the firm. Sometimes, higher debt can also give the firm the benefit of 
financial leverage. 
Formula: Total Debt / Total Assets 
 
0
10
20
30
40
50
60
70
80
90
1 2 3 4 5 6
65.42
81.25
49.43 46.52
30.93 32.03
Days sales outstanding
Days sales outstanding
  
 
Debt Ratio of GSK:  
Year 2007 2008 2009 2010 2011 2012 
Debt Ratio .25 .33 .32 .38 .49 .52 
 
Table 10: Debt Ratio 
 
 
 
                2007               2008           2009        2010          2011         2012 
A debt ratio less than .50 is considered as good, from the year 2007 to 2010 the debt ratio of 
GSK was impressive as the debt ratio was less than .50 at those years.  In 2011 the ratio was very 
near to .5 and in 2012 it was more than .5 which is not fruitful for the business and it signals 
towards higher dependency on debt.  
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4.11 Debt to Equity Ratio: The debt to equity ratio is the best way to measure the financial 
leverage of any firm; it is one of the most important ratios of any firm. Higher the ratio, higher 
the debt amount of the firm, therefore higher financial leverage. 
If the ratio is lower, the leverage of the firm is also lower. It presents the parentage of a 
company’s asset that is financed by debt versus equity. It is a widespread quantity of the long 
term capability of a firm’s business and along with current ratio, a measure of its liquidity, or its 
ability to cover its expenses. So, it often takes only long term debts instead of total liabilities. 
Sometimes, it happens that higher debt leads the firm to gain higher debt as cost of debt is lower 
than the cost of equity but it is not good for the firm to always apply this technique because if the 
firm fails to meet up the obligations of debts ten the firm can reach even in the stage of the 
bankruptcy. So, the firms should be much analytical and attentive when to take higher debts. 
Higher debt can lead to both higher gain and risk, so firms should be very careful while taking 
financial leverage. 
Formula: Total Debt / Shareholder’s Equity 
Debt to Equity Ratio of GSK:  
Year 2007 2008 2009 2010 2011 2012 
Debt  to 
Equity 
Ratio 
.34       .49 .46 .60 .96 1.06 
 
Table11: Debt to Equity Ratio 
 
  
 
 
                 2007     2008      2009      2010      2011     2012 
The debt to equity ratio had a upward tend over the six years which indicates that GSK is taking 
more financial leverage and also depending on more debts. In 2011 and 2012 the ratio were too 
high, it was .96 and 1.06 respectively which might lead the firm towards huge risk. Yes, higher 
debt can increase the earnings a lot but it is only possible when the cost of debt is affordable by 
the company. 
             
4.12 Time Interest Earned Ratio: Time Interest Earned ratio is basically a solvency ratio which 
assesses that firm has the capacity or not to pay back all its loans. This ratio is also known as 
interest coverage ratio. Through this ratio it can be judged that how many times a firm can face 
its interest expenses that are due to the taken borrowings. If the ratio is higher, then it means that 
the firm has the ability to payback its loans but if the amount is too high then it mean that the 
firm is unnecessarily using the maximum portion of earnings to repay the loans. So, it means that 
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in this case the company can afford using low portion of returns in repayment of loans and can 
reinvest the earnings on more volume in order to ensure high growth. On the other hand, if the 
ratio is less than 1 then it means that the firm is not achieving much profit to meet up the debt 
obligations. 
 
Formula: Earnings Before Interest and Tax / Interest Expenses 
 
Time Interest Earned Ratio of GSK:  
Year 2007 2008 2009 2010 2011 2012 
Time 
Interest 
Earned 
Ratio  
16.82       24.28 528.06 674.10 123.79 79.5 
 
Table 12: Time Interest Earned Ratio 
 
 
  
 
 
                   2007      2008     2009      2010     2011     2012 
In 2007 and 2008, the interest coverage ratio was relatively very low and it indicates that then 
GSK was not much efficient to pay back its interests from the earnings but there is a conflicting 
point and that is, the ratio is greater than 1 which means the firm can meet up the obligation, yes 
of course more high the ratio then the firm is more capable but by the two figures of 2007 and 
2008 we can not say that GSK failed, GSK then definitely had enough capacity. So, we can say 
that it could have been better. In 2009 and 2010 the ratio was abnormally which is also not good 
for business and indicates that the money is being spent much on repaying debts rather than 
reinvesting. It means that the firm has now fewer debts so they can concentrate on more business 
growth but they are not doing so. In 2011 and 2012 the ratio decreased rapidly, which signals 
that the firm has less debts and at the same time now they have realized the importance of 
business extension. 
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4.13 Gross Profit Margin: Profitability depends on a large number of policies and managerial 
decisions of a firm. All the effects of liquidity, asset and debt management on the income s 
judged through the profitability ratios. Gross profit Margin, Profit Margin, Return on Assets and 
Return on Equity are the mostly used profitability ratios. 
The relationship of sales and cost of goods sold is assessed through gross profit margin. High 
ratio indicates a secure position for the company. Low profit margin signals towards less safe 
position because it means that sales are diminishing, therefore generating low revenues. It is also 
a great tool of identifying pricing strategy and cost control. It helps to cut cost by presenting that 
cost is relatively low or high than the revenues. So, from the low profit margin we actually get 
the idea that I which way we need to control our costs. 
Formula:  
Gross Profit Margin = Gross Profit / Sales 
 
Gross Profit Margin of GSK:  
Year 2007 2008 2009 2010 2011 2012 
Gross Profit 
Margin 
.22        .25 .31 .34 .28 .29  
 
Table 13: Gross Profit Margin of GSK 
 
 
 
  
 
 
                   2007         2008          2009        2010         2011     2012 
Over the first four years, the gross profit margin has increased gradually by slight amount every 
year but in 2011 there was a downfall and in 2012 it increased by only one point. In 2011 the 
sales were higher than previous four years but the costs associated with the sales were also too 
high, for this reason the margin was low. From this result, GSK tried to control the cost and as a 
result the situation was little better in 2012 than that of 2011. One positive thing we can notice 
that the performance of GSK was quite stable in terms of gross profit margin which means 
throughout these years the GSK Bangladesh Ltd faced less fluctuations, therefore had much 
secured position. 
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4.14 Operating Profit Margin: This ratio is another important tool to measure the profitability 
of the firm. Firstly, the operating profit means the profit which is gained through the core 
business operations, not from the financing or investing activities. This profit is also known as 
Earnings Before Interest and Tax (EBIT). Operating Profit= Operating Revenue-Cost of Goods 
Sold- Operating Expenses-Depreciation and Amortization. 
This operating profit is used to calculate the operating profit margin which clarifies that how 
efficiently and effectively the firm is doing operations and making money. High operating profit 
margin indicates that the firm is good at merchandising activities, they are low cost producers so 
capable to offer cheap price to the customers and this manner they are making high profit than 
the competitors. The operating profit margin, also clarifies another major thing that is, how much 
operating profit a company makes on each dollar of sales. Higher operating profit margin 
indicates a healthy business. In order to judge that the operating profit margin is impressive or 
not, we need to observe that the ratio is increasing over time or not, if the trend is increasing then 
definitely the firm’s efficiency to make profit from sales is increasing. 
Formula:  
Operating Profit Margin = EBIT / Net Sales 
Operating Profit Margin of GSK:  
Year 2007 2008 2009 2010 2011 2012 
Operating 
Profit 
Margin 
.05        .11 .14 .15 .09 .07 
 
Table 14: Operating Profit Margin 
 
 
  
 
 
                   2007     2008      2009     2010     2011      2012 
 
From the year 2007 to 2010 the operating profit margin was quite impressive as it was in 
increasing trend but in the year 2011 it took a downfall which means on that year the sales 
revenue was less than previous years and it also indicates poor management and pricing strategy. 
Then in the year 2012 the scenario was worse because the downfall continued. 
 
4.15 Net Profit Margin: This is the ratio of Net Income to Sales or Revenues. Through the net 
profit margin, we asses that out of each dollar of sales, how much is kept as earning. This is also 
known as profit margin. Higher the profit margin, better the condition of the firm. Higher profit 
margin means that from the sales, higher portion is remaining as profit so it also indicates 
towards efficient expense controlling ability.  
Formula of Net Profit Margin= Net Income/Sales 
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Net Profit Margin of GSK 
Year 2007 2008 2009 2010 2011 2012 
Net 
Profit 
Margin 
.03        .08 .11 .11 .06 .04 
 
Table 15: Net Profit Margin 
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In the year 2007 the profit margin was very low but in 2008, 2009 and 2010 there was uphill in 
profit margin which means then revenue was higher and expenses were also lower. However, in  
2011 it fell by .05 and in 2012 it again reduced by .02 so GSK should be more concern in 
expense management pricing policies. 
 
4.16 Return On Assets (ROA): ROA is the measurement tool by which we can know that a 
firm is how much profitable in comparison with its total assets. So, it measures that the firm how 
efficiently uses its assets to generate profits. This is also known as Return On Investment (ROI) 
as it tells that a firm how effectively transforms its investments on profits. It is often expressed in 
percentage. Higher ROA is always desired as it indicates that higher profit has been made 
through fewer investments. 
Formula:  
ROA=Net Income/Total Assets  
 
ROA of GSK: 
Year 2007 2008 2009 2010 2011 2012 
ROA .04        .10 .19 .19 .11 .08 
 
Table16: ROA 
 
  
 
 
                       2007         2008          2009         2010          2011          2012 
In 2007 the ROA was 4% and then it rose to 10% in 2008 which indicates successful 
management policies of GSK. Then in 2009 and 2010 the ROA was 19% which is very 
impressive but in 2011 it decreased by 8%. In 2012 the ROA was 8%, so there was again 
downfall but this year the percentage of downfall was lower than that of 2011. 
 
4.17 Return On Equity: Return On Equity or ROE is the ratio of net income to total 
shareholder’s equity. It measures that the firm how much earns from the shareholders’ equity. It 
also shows the firm’s efficiency at generating profits from every dollar of equity capital. 
Increasing ROE indicates improved performance. In accounting sense, ROE is the true bottom 
line of performance measurement. 
 
Formula:  
ROE= Net Income/Total Equity Capital 
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ROE of GSK: 
Year 2007 2008 2009 2010 2011 2012 
ROE 5.64%       15.67% 27.82% 29.70% 19.83% 16.42% 
 
Table 17: ROE 
 
 
 
                           2007           2008          2009         2010            2011           2012 
The graph interprets that, from 2007 to 2010 there was a huge improvement in ROE, over these 3 
years it increased by almost 24% but in 2011 it decreased by 19.83% which is not a good 
indication. In 2012 the downfall continued which indicates that GSK’s management efficiency is 
lower than previous years and it is earning less profit from the equity capital. 
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4.18 Earning Per Share:  Earning per share or EPS expresses the earned profit against per 
share. It is considered as an important tool while measuring a stock’s performance. Investors 
often judge the firms with the EPS and always prefer a high EPS. However, always high EPS 
does not mean that the firm is doing well because the Net income can be manipulated and for this 
reason EPS can be overestimated. Often firms do these in order to attract the public. So, relying 
only on EPS is never a wise decision. Another important point is, same EPS of two firms do not 
indicate that the firms are equally strong; here we need to judge that which firm has earned same 
EPS by less investment. The firm which has done so is in better position and more efficient. 
Formula: Net Income/ Number of Common Stock Outstanding 
EPS of GSK: 
Year 2007 2008 2009 2010 2011 2012 
EPS 3.74 TK  11.87 TK 26.88 TK 34.05 TK 23.42 TK 20.25 TK 
 
Table18: EPS 
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In the year 2007, the EPS was very low but up to 2010 it increased a lot which indicates that 
earnings against each share were high on those years. In 2011 the EPS dropped by 10.63tk and in 
2012 it again dropped by 3.17 tk. So, GSK should take initiative to increase the EPS otherwise it 
may create confusion about the financial condition to the general public. 
 
4.19 Payout Ratio: The dividend payout ratio is actually the percentage of earnings that is given 
to the investors of the firm. High payout ratio always attracts the investors because it means that 
the firm is in good position and generating huge profit. That’s why investors always seek for 
high dividends and often switch to another stock in order to fulfill their desire.  It is not always 
true that firms in good condition can only afford dividend payment, it also happens that a firm 
with a future growth prospect currently giving low or zero dividends but in long run it will 
provide the investors high capital gain. So, investors should not only seek high dividends, they 
should be more aware about high capital gain. Sometimes, excess amount dividend payment is a 
bad sign, it indicates that organization is wasting money unnecessarily rather than reinvesting 
from which future of the business could be more secured. 
Formula: 
Dividend Payout Ratio = Total Dividend/ Net Income 
Dividend Payout Ratio of GSK: 
Year 2007 2008 2009 2010 2011 2012 
Dividend 
Payout 
Ratio 
.27       .21 .22 .47 .85 .74 
 
Table19: Payout Ratio 
 
  
 
 
                   2007       2008       2009        2010         2011       2012 
In 2007 to 2009, although there was a downfall in payout ratio but the ratio did not fluctuated 
much, so almost a stable ratio was maintained which is a positive thing. In 2010 the payout ratio 
was much higher than 2009 which symbolizes GSK’s strong financial condition. In 2011 the 
ratio was very high which is not good, it means then GSK gave less concentration in future 
growth. In 2012, although the ratio is lower but still it is very high. 
 
 
4.20 Price Earnings Ratio or P/E: This is the ratio of market value to EPS. Through this ratio, 
the recent trading price of the firm is compared with its EPS. 
The P/E ratio actually represents the expectation of investors about the firm. Higher P/E means 
that investors have high expectations about the firm’s future growth and that’s why they are 
interested to invest. 
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The P/E ratio has also another meaning, sometimes it also indicates that how much the investors 
are willing to pay for per dollar of earnings. So, in this case it is referred as multiple. The average 
P/E ratio is 20-25 times. Comparing P/E ratio within firms of same industry gives the idea that 
which firm is performing well. 
 
Formula: 
P/E ratio= Market Price/EPS 
P/E Ratio of GSK: 
Year 2007 2008 2009 2010 2011 2012 
P/E  Ratio 51.60       27.81 26.98 33.17 28.39 28.15 
Table20: P/E Ratio 
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Over the last six years, the P/E ratio of GSK was quite high which means that investors have 
great interest on GSK, this is because GSK is a well reputed multinational firm and has a unique 
brand image. In 27 the ratio was abnormally high which means it was over valued and in 2008 it 
was much lower than 2007 but higher than the standard figure. From 2009 to 2010, there was a 
raise in P/E. In 2011 there was a little downfall and in 2012 it was very near to that of 2011. So, 
from 2009 to 2012 it is quite stable but still higher than standard which indicates that people 
have positive opinion about the stocks of GSK. 
 
4.21 Basic Earnings Power: It is the ratio of Earnings Before Interest and Taxes to Total Assets. 
This ratio tells us that the firm is how much efficient at earning EBIT from its total assets. High 
BEP is considered as good for firm. 
Formula: 
Basic Earnings Power (BEP) = EBIT/ Total Sales 
Basic Earnings Power of GSK: 
Year 2007 2008 2009 2010 2011 2012 
Basic 
Earnings 
Power 
.07       .16 .25 .24 .16 .12 
 
Table 21: Basic Earnings Per Share 
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In 2007 the BEP was lower, but I 2008 and 2009 it increased at a satisfied manner. In 2010 it 
dropped a little but in 2011 and 2012 the downfall continued at an increasing manner. So, it 
indicates that in the last three years the GSK Bangladesh Ltd did not utilize its assets properly to 
earn higher EBIT. 
Book Value per Share: The book value per share represents the value which is leftover for the 
common stockholders after paying all debts and liquidating all the assets. So, if any firm 
becomes bankrupt then this is the value which the investors get back. So, it ensures that 
investment on a firm is safe or not. 
Formula: 
Book Value per Share = (Asset-Liabilities) / Number of Shares Outstanding 
Book Value per Share of GSK: 
Year 2007 2008 2009 2010 2011 2012 
Book Value 
Per Share 
66       76 97 115 118 123 
Table 22: Book Value per Share 
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                    2007     2008      2009     2010       2011     2012 
Over the last six years, the book value per share of GSK has increased day by day. Compared to 
2007, the book value per share is 57 taka higher in 2012 which is really impressive and indicates 
that the firm has a high growth. On the other hand, the market value is much higher than the 
book value which means that currently the stock is over valued so there is a chance of downfall 
in prices in future. 
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4.23 Findings 
 
The factors I have identified through my analysis are: 
 GSK has a very little amount of long term debt 
 GSK earns a significant amount every year, its current ratio and turnover ratios 
are satisfactory which indicates that GSK is performing well. 
 GSK has enormous production capacity but it is not fully utilizing this 
opportunity and it is not producing cheaper products than the competitors. 
 GSK has a policy, that the MPOs can not pursue the doctors to recommend its 
drugs and as a result it is lagging behind in this sector. 
 GSK’s distribution channel is not that much strong compare to the local firms. 
 GSK is not under capitalized which means GSK does not only depend on 
borrowed capital and the creditors. So its owned capital is able to meet up the 
operational costs. So, obviously GSK is financially solvent. 
 
 
 
 
 
 
 
 
 
  
 
 
 
 
 
 
 
 
 
 
 
Chapter 5 
Recommendation and Conclusion 
 
 
 
 
 
 
 
  
 
 
5.1 Recommendations 
 Although GSK is maintaining a fair current ratio, but from 2009 to 2012 it is 
gradually decreasing which is an indication that current liabilities are 
increasing. So, GSK must concentrate on this issue and should be careful to 
control the debts. 
 The debt ratio of GSK is not so high but it is increasing gradually and in 2012 
it was above .52. Although the figure is no so violent but if it is below .5 then 
more secured condition is expressed. So, from now GSK should check that its 
dependency on the trade creditors is increasing or not. If it is increasing then 
GSK must take effective steps to reduce it. 
 There is an upward trend in debt to equity ratio, again it is pointing out that 
debts are increasing. Although higher debts can give financial leverage but 
there is also a risk of meeting up the debt obligations. So, GSK should realize 
that higher debts can lead it to higher risk. From now it should be little 
conservative in case of taking debts. 
 Most of the profitability ratios are decreasing. So, it means the growth is 
lowering day by day. In this case GSK must needs to think that how more 
profit can be achieved and needs to find ways to capture the significant portion 
of the market thus profit level goes up. 
 In 2011 the sales growth was much higher than 2010 and in 2012 this trend 
was maintained. Although it’s a very positive indication but GSK should not 
forget that it can increase the market share more. So, in this regard it should 
increase the promotional activities to capture the consumer mind more. 
 Market coverage can be expanded through reaching the every corner of the 
country. GSK needs to adopt more aggressive strategy in order to beat the 
competitors. 
 GSK needs to change its policy of not pursuing the doctors to prescribe its 
drugs, otherwise it will not be able to cope up with the local giants. 
 
  
 
 
 
 
5.2  Conclusion 
 
Financial ratios analysis is a part of financial statement analysis and through 
this we can have knowledge about the company’s past and present 
performance. Most importantly it gives us an idea that what can be the 
company’s performance in the future. Ratio analysis involves the calculation of 
statistical relationship between data and it is a very popular technique of 
financial statement analysis. Throughout my analysis, I came to know about 
the financial strength, operational efficacy and management efficacy of GSK. I 
have realized that GSK is performing well, it is financially solvents but there 
some threats which are increasing recently. If the risks or threats can behandled 
properly then definitely GSK can survive successfully as like the previous 
years. 
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